Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:40:33.803Z.
Calculation as of: 2026-10-06T19:40:33.803Z.
Quote observation: 2026-10-06T19:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 236ecad6846b0cc00793ea2ceb9f38c60eee5e96b58175726d9ae7432cdeb63e
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $665.22M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 114.38 | 37.43 | 206.22 | 206.22 |
| Helus Pharma Inc. (HELP)vs › | $660.66M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $658.58M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $658.16M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $674.85M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $682.79M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $685.85M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $686.42M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $688.40M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.06
Forward EPS (Est.)
$-1.05
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
